The Maharashtra Food and Drug Administration intensified regulatory enforcement after seizing medicines worth Rs 73.24 lakh during statewide raids targeting allegedly misleading healthcare advertisements. Products manufactured by Divya Pharmacy and marketed under the Patanjali label were among the medicines confiscated. According to the FDA, the action was conducted under provisions of the Drugs and Magic Remedies (Objectionable Advertisements) Act. Officials alleged that certain advertisements made claims regarding guaranteed cures for serious illnesses, including cancer and diabetes. The enforcement drive follows the appointment of Tukaram Mundhe as commissioner.
Patanjali Products Among Medicines Worth Rs 73 Lakh Seized by Maharashtra FDA Over Allegedly Misleading Advertisements
The Maharashtra Food and Drug Administration has seized medicines worth more than Rs 73 lakh, including products manufactured by Divya Pharmacy and marketed under the Patanjali brand, during a statewide enforcement drive targeting allegedly misleading medical advertisements.
The Patanjali products seizure case has drawn attention after the Maharashtra Food and Drug Administration (FDA) confiscated medicines worth Rs 73.24 lakh during coordinated raids across multiple regions of the state.
According to the FDA, the action was carried out under the provisions of the Drugs and Magic Remedies (Objectionable Advertisements) Act, which regulates advertisements making prohibited medical claims to consumers.
The raids were conducted simultaneously across Mumbai, Konkan, Pune, Nashik, Amravati, Nagpur, and Chhatrapati Sambhajinagar divisions, targeting medicines allegedly promoted through objectionable or misleading advertisements that could influence public healthcare decisions.
FDA officials stated that medicines manufactured by Divya Pharmacy, Haridwar, and marketed under Baba Ramdev’s Patanjali brand were among the products seized during the enforcement operation conducted across Maharashtra.
In the Nagpur division, authorities seized medicines valued at Rs 7,26,755 manufactured by Divya Pharmacy. In the Nashik division, officials confiscated additional stocks reportedly valued at Rs 7,10,945.
Maharashtra FDA Targets Alleged Misleading Health Claims
According to information released by the FDA, several advertisements under scrutiny allegedly contained claims suggesting guaranteed or complete cures for serious medical conditions, raising concerns about regulatory compliance.
Officials stated that some promotional materials reportedly promised “100 per cent treatment” outcomes and included references to miraculous or extraordinary healing effects without presenting recognised scientific evidence supporting such claims.
The FDA indicated that certain advertisements allegedly referred to the treatment of serious diseases, including cancer and diabetes, while making claims that authorities believe may mislead consumers seeking medical solutions.
The action comes shortly after senior bureaucrat Tukaram Mundhe assumed charge as Commissioner of the Maharashtra Food and Drug Administration, initiating a series of enforcement measures targeting public health violations.
According to official statements, Mundhe had previously warned that individuals or organisations found endangering public health or misleading consumers would face strict regulatory action under applicable laws.
The agency further stated that advertisements and product promotions are being examined for possible violations of the Drugs and Cosmetics Act, 1940, in addition to provisions governing objectionable medical advertisements.
Tukaram Mundhe’s Early Enforcement Drive Draws Attention
The latest action forms part of a broader enforcement campaign launched by the FDA following Mundhe’s appointment, reflecting a more aggressive regulatory approach toward consumer protection and healthcare compliance.
According to official figures, FDA teams conducted raids at 53 locations across Maharashtra within the first three days of the new commissioner’s tenure, targeting food adulteration and regulatory violations.
Authorities reported that action taken during these operations resulted in the arrest of 33 individuals allegedly connected to food adulteration and related offences affecting public health and consumer safety.
The enforcement drive has generated discussion among healthcare professionals, consumer rights advocates, and regulatory observers regarding the growing scrutiny of medical advertising and product marketing practices.
Consumer protection experts have long argued that unverified healthcare claims can influence treatment decisions, particularly among vulnerable patients seeking remedies for chronic or life-threatening illnesses.
The FDA has reiterated that entities found to violate advertising and drug regulations may face legal proceedings, including prosecution before appropriate courts, depending on the findings of ongoing investigations.
Also Read: Western Park Redevelopment Complaints Intensify.
Broader Implications for Healthcare Advertising Compliance
The Maharashtra FDA action highlights growing regulatory scrutiny of healthcare advertising standards and the responsibility of manufacturers, distributors, and marketers to ensure accuracy in promotional communications.
Regulators across India have faced growing pressure to monitor medical advertisements more closely amid concerns that exaggerated health claims may undermine informed consumer decision-making and public trust.
While investigations and regulatory proceedings continue, the latest seizures signal that authorities intend to intensify scrutiny of advertisements making therapeutic claims that may not meet statutory requirements.
As enforcement actions progress, industry participants, healthcare providers, and consumers are expected to closely monitor developments that could influence future standards governing the marketing of medicines and healthcare products.
Sprouts News will continue monitoring developments related to the Maharashtra FDA investigation and any subsequent regulatory or legal proceedings arising from the seizures.
Readers’ Appeal
Unmesh Gujarathi, an investigative journalist and Editor-in-Chief of Sprouts News, has consistently reported on issues relating to consumer rights, public health, regulatory compliance, and alleged misleading claims associated with various products and organisations, including those linked to Patanjali.
Readers, whistleblowers, industry professionals, former employees, healthcare experts, and consumers possessing credible information, documents, records, or evidence relating to product claims, regulatory violations, consumer grievances, or matters of public interest may confidentially contact the Sprouts News investigation team at 9322755098. All information will be reviewed in the public interest and treated with appropriate confidentiality.
Editorial Note:
This article is based on publicly available FIR records, court case references, and reports published by multiple media organisations. The information is presented in the context of ongoing investigations and public interest reporting. Sprouts News does not make any judicial determination regarding the individuals mentioned and does not intend to defame any person or organisation. Any individual seeking clarification or wishing to provide an official response may contact the editorial team with verifiable documentation. The information is presented for journalistic and informational purposes.
